Alto Neuroscience Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Alto Neuroscience Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Mountain View
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ANRO
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001999480
- EIN
- 83-4210124
Board of directors
-
Amit Etkin · Director · PRESIDENT AND CEOSince 2024
-
Andrew Craig Miller · DirectorSince 2026
-
Andrew Dreyfus · DirectorSince 2024
-
Christopher Nixon Cox · DirectorSince 2024
-
Gwill York · DirectorSince 2024
-
Husseini Manji · DirectorSince 2024
-
Maha Radhakrishnan · DirectorSince 2024
-
Po Yu (Jeff) Chen · DirectorSince 2024
-
Ramiro Sanchez · DirectorSince 2025
Chief executives
Amit Etkin
· PRESIDENT AND CEO
Since February 2024
Director election results
Annual meeting of May 12, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
53.5%
-
99.9%
Board connections
5 of this board's directors also sit on 7 other boards.
- via Maha Radhakrishnan
- via Maha Radhakrishnan
- via Christopher Nixon Cox
- via Andrew Dreyfus
- via Andrew Craig Miller
- via Christopher Nixon Cox
- via Ramiro Sanchez
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 14, 2026 | Amit Etkin Director, Officer (PRESIDENT AND CEO) | Gift | −400,000 | — | — |
| Mar 1, 2026 | Amit Etkin Director, Officer (PRESIDENT AND CEO) | Shares withheld for tax | −6,227 | $19.69 | $122,610 |
| Mar 1, 2026 | Smith Nicholas Conrad Officer (CHIEF FINANCIAL OFFICER & CBO) | Shares withheld for tax | −2,806 | $19.69 | $55,250 |
| Jul 10, 2024 | Savitz Adam Officer (CHIEF MEDICAL OFFICER) | Open-market purchase | +2,931 | $13.22 | $38,748 |
| Jul 9, 2024 | Savitz Adam Officer (CHIEF MEDICAL OFFICER) | Open-market purchase | +10,681 | $12.53 | $133,833 |
| Jul 9, 2024 | Savitz Adam Officer (CHIEF MEDICAL OFFICER) | Open-market purchase | +1,388 | $13.15 | $18,252 |
| Mar 28, 2024 | Smith Nicholas Conrad Officer (CHIEF FINANCIAL OFFICER) | Open-market purchase | +1,600 | $15.80 | $25,280 |
| Mar 28, 2024 | Smith Nicholas Conrad Officer (CHIEF FINANCIAL OFFICER) | Open-market purchase | +4,550 | $16.56 | $75,348 |
| Mar 1, 2024 | Smith Nicholas Conrad Officer (CHIEF FINANCIAL OFFICER) | Grant or award | +19,153 | — | — |
| Mar 1, 2024 | Amit Etkin Director, Officer (PRESIDENT AND CEO) | Grant or award | +34,711 | — | — |
| Feb 6, 2024 | Apeiron Investment Group Ltd. See Remarks | Derivative conversion | +251,881 | — | — |
| Feb 6, 2024 | Alpha Wave Global, LP 10% owner | Derivative conversion | +1,962,995 | — | — |
| Feb 6, 2024 | Gwill York Director | Derivative conversion | +23,917 | — | — |
| Feb 6, 2024 | Smith Nicholas Conrad Officer (CHIEF FINANCIAL OFFICER) | Open-market purchase | +1,563 | $16.00 | $25,008 |
| Feb 6, 2024 | Christopher Nixon Cox Director | Derivative conversion | +588,898 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.